Amadeus Capital
Perman Jorayev
Perman Jorayev
Perman is an Investor in the Amadeus Early Stage team. Previously, Perman worked at Verve Ventures, establishing their UK office and investing across Health & Bio, AI, Materials, and Quantum.
Perman holds a PhD from University of Cambridge in Chemical Engineering with a research focus on AI-driven autonomous labs for process development. During his PhD, Perman collaborated with multiple pharma companies to develop new drug synthesis workflows.
Perman holds a BSc in Chemistry and Chemical & Biomolecular Engineering from KAIST, Korea with research experience at EPFL, Switzerland and MIT, USA in carbon capture, live cell protein imaging, crude-oil upgrading, and synthetic chemistry.
Inveready
Antonio Herce
Antonio Herce
Antonio joined Inveready in 2019 and serves as Investment Director, leading deal sourcing, due diligence, and portfolio management. He currently sits on the boards of Atlas Molecular Pharma, Galgo Medical, and Nanoligent.
With a background in Biotechnology, Antonio has held roles in technology transfer and business development across research institutions and startups. He has driven the creation of academic spin-offs and led licensing and collaboration agreements with biotechnology and pharmaceutical companies.
Pictet
David Braga
David Braga
David Braga Malta joined Pictet in 2021. adding to the Thematic Private Equity franchise expansion into healthcare co-leading it. David is a Life Sciences investor and entrepreneur experienced in novel drugs and digital health solutions. David brings more than 10 years of experience in the field. His PhD thesis gave rise to a first company in the advanced therapy field, and a second pioneering the field of neuro-immune regulation.
As an investor, David has experience both as a fund of fund investor and as a direct investor. He helped Caixa Geral de Depósitos to launch a direct and indirect investment strategy in healthcare and more recently as a Venture Partner of Vesalius Bio-capital venture capital fund in Europe.
Ysios
Guillem Laporta
Guillem Laporta
Guillem Laporta is a Partner at Ysios Capital, where he focuses on life sciences investments in Europe and the US. Prior to joining the firm, he was at Edmond de Rothschild Group (now Andera Partners) in Paris, where he was involved in investments including Reviral (acquired by Pfizer), Axonics (Boston Scientific), Sanifit (Vifor), and Verona Pharma (NASDAQ: VRNA). He holds degrees in Biotechnology from the Universitat Autònoma de Barcelona and in Business Administration from the Universitat Pompeu Fabra, and is a CFA charterholder. Guillem currently serves on the boards of ReproNovo, VarmX, and Kynexis, and is a board observer at Engrail Therapeutics.
